Rheumatoid arthritis: All clear for Janus kinase inhibitors

Data from 13 registers Rheumatoid arthritis: All clear for Janus kinase inhibitors

Further registry data presented at the European Congress of Rheumatology 2025 show that the cancer risk with Janus kinase inhibitors is not significantly increased in clinical practice – a reassurance for use in other indications.